Thurgauerstrasse 130
8152 Glattpark-Opfikon
Switzerland

09/11/2023

[redacted]

Re: Your medical information request, Ref: [redacted]

Dear [redacted]

Thank you for your medical information request. You requested information on the availability of Elvanse and Elvanse Adult.

In response to your request regarding Elvanse® (lisdexamfetamine dimesylate) and Elvanse Adult® (lisdexamfetamine dimesylate) we are providing the following information:

We currently have supply interruptions with all Elvanse and Elvanse Adult strengths and we are working with our supply teams to address these interruptions as quickly as possible. Maintaining continuity of supply is of utmost importance to us and we appreciate how difficult this situation is for individuals and their families.

Limited stock of different dose strengths across our ADHD products are becoming available at various times. We are working with our teams to replenish supply across all impacted products as quickly as possible. However, we are anticipating that disruption across all dose strengths of Elvanse will continue intermittently until April 2024.

Whilst the exact duration of the shortage is unknown, the current anticipated date of availability (at the time of writing) for limited stock of Elvanse 30mg, 40mg, 60mg and 70mg is from the week commencing 12/01/2024, 01/01/2024, 27/11/2023, and 20/11/2023 respectively.

Limited stock of Elvanse 20mg, Elvanse 50mg and all Elvanse Adult strengths are intermittently available and can be ordered via our distributor. However, there are allocations in place with our distributor, to ensure equitable access to products as they become available across the country. These quotas are based on previous ordering and usage patterns. Unfortunately, the quotas mean that customers are not able to access the quantity of packs they require in full. However, this is the only way we can ensure equitable distribution of remaining stock between all customers trying to access medication.

We apologise for the disruption this is causing and we are working with our supply teams to address these interruptions as quickly as possible.

The demand for ADHD medicines has risen substantially over the past 2 years and continues to do so. This increase in demand has, in part, impacted our supply in the form of ongoing shortages which we are continuously working hard to address in order to support patients and the clinical community in the best way that we can. Takeda is transferring manufacturing operations to an upgraded internal facility in mid-2024. Takeda made this decision in the best interest of patients and to ensure future supply consistency. We are doing our utmost to ensure a continued supply and sincerely appreciate your patience and understanding during this period.

This information is provided as a professional courtesy in response to your inquiry. It is intended to provide pertinent data to assist you in forming your own conclusions in order to make healthcare decisions. Takeda does not advocate the use of its products outside of approved labeling or the use of investigational drugs not approved by the local health authority. Please refer to the full Prescribing Information.

Please let us know if you would like to be contacted by the local Medical Affairs team for further information.

If you have additional questions, or to report an adverse reaction please contact Takeda Medical Information at +44 (0)3333 000181 or medinfoemea@takeda.com

Sincerely,

[redacted]
Takeda Medical Information
This is a response to an unsolicited request and may contain information outside of the product license. It should not be forwarded or copied.

REFERENCES

Takeda Internal data ([redacted]). Lisdexamfetamine Dimesylate shortage. October 2023

Please be advised that the current Summary of Product Characteristics (SmPC) is available on the eMC at: www.medicines.org.uk/emc

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Takeda UK Ltd at AE.GBR-IRL@takeda.com.